CHChai Zhen Hoo

Chai Zhen Hoo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chai Zhen Hoo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Amy Hicks

    Leeds Liver Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK

    1 shared publication
  • Benedict Lim-Heng Sim

    Department of Medicine, Sungai Buloh Hospital, Selangor, Malaysia

    1 shared publication
  • Bin Gao

    Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.

    1 shared publication
  • Haniza Omar

    Department of Hepatology and Gastroenterology, Selayang Hospital, Selangor, Malaysia

    1 shared publication
  • Joanna Moore

    Leeds Liver Unit, Leeds NHS Teaching Hospitals Trust, Leeds, UK; Leeds Institute for Medical Research, University of Leeds, Leeds, UK

    1 shared publication
  • Kar-Choon Tan

    Department of Hepatology and Gastroenterology, Selayang Hospital, Selangor, Malaysia

    1 shared publication

Latest Publications

  • Novel treatment of acute and acute‐on‐chronic liver failure: Interleukin‐22

    by Seonghwan Hwang, Amy Hicks, Chai Zhen Hoo, Yong Seong Kwon, Ye Eun Cho, Joanna Moore, Bin Gao

    Acute liver failure (ALF) is a life‐threatening medical condition, characterized by rapidly progressive hepatic dysfunction, coagulopathy and hepatic encephalopathy in patients without chronic liver disease, while acute‐on‐chronic liver failure (ACLF) occurs in patients with existing chronic liver disease. ALF and ACLF are often associated with multiple organ failure and a high short‐term mortality. In this review, we briefly discuss the causes and pathogenesis of ALF and ACLF, the current options available for the treatment of both deadly maladies and interleukin‐22 (IL‐22), a novel promising drug that may have great therapeutic potential for ALF and ACLF treatment. IL‐22 is a cytokine produced by immune cells but mainly targets epithelial cells including hepatocytes. IL‐22 has been shown to protect against organ damage and reduce bacterial infection in many preclinical models and several clinical trials including alcohol‐associated hepatitis. The potential application of IL‐22 for the treatment of ALF and ACLF is also elaborated.


  • Open Access

    Severe Hepatocellular Liver Injury After COVID-19 Vaccination Without Autoimmune Hepatitis Features: A Case Series

    by Chai-Zhen Hoo, Kar-Choon Tan, Salmi Abdullah, Benedict Lim-Heng Sim, Haniza Omar, Soek-Siam Tan

    Various vaccines were developed and administered to end the pandemic caused by the novel coronavirus diseases 2019 (COVID-19). These vaccines caused rare side effects not known during clinical trials. We report 2 cases of idiosyncratic drug-induced liver injury where the Pfizer BioNTech COVID-19 mRNA vaccine was administered. Both cases showed hepatocellular liver injury with negative autoimmune features on serology and histology and progressed to a protracted course of severe jaundice and pruritus before resolving without any immunosuppressants. We hope to raise awareness of possible rare side effects of the COVID-19 vaccine so that physicians can be vigilant.